Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management

References

• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Pacheco JM, Camidge DR, Doebele RC, et al. A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. Front Oncol. 2019;9:195.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, et al. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.
   Web of Science ®Google Scholar
• Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open. 2019;2(5):e192535.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–1855.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395–1408.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–546.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• Bardhan K, Anagnostou T, Boussiotis VA. The PD1: PD-L1/2Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14(10):569–579.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.
   PubMed Web of Science ®Google Scholar
• Dupont R, Berard E, Puisset F, et al. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. Oncoimmunology. 2020;9(1):1682383.
   PubMed Web of Science ®Google Scholar
• Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785–792.
   PubMed Web of Science ®Google Scholar
• Xing P, Zhang F, Wang G, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019;7(1):341.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Grizzi G, Ghidini M, et al. Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 2020;43(1):1–7.
   PubMed Web of Science ®Google Scholar
• Nordlund JJ, Kirkwood JM, Forget BM, et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;9(5):689–696.
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51.
   PubMed Web of Science ®Google Scholar
• Quach HT, Dewan AK, Davis EJ, et al. Association of anti-programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. JAMA Oncol. 2019;5(6):906–908.
   PubMed Web of Science ®Google Scholar
• Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5(7):1043–1047.
   PubMed Web of Science ®Google Scholar
• Joshi MN, Whitelaw BC, Palomar MT, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016;85(3):331–339.
   PubMed Web of Science ®Google Scholar
• Garon-Czmil J, Petitpain N, Rouby F, et al. Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French pharmacovigilance database. Sci Rep. 2019;9(1):19419.
   PubMed Web of Science ®Google Scholar
• Jennings JJ, Mandaliya R, Nakshabandi A, et al. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol. 2019;15(3):231–244.
   PubMed Web of Science ®Google Scholar
• Mohn N, Beutel G, Gutzmer R, et al. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook. J Clin Med. 2019;8(11):1777.
   PubMed Web of Science ®Google Scholar
• Tan MH, Iyengar R, Mizokami-Stout K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1.
   PubMedGoogle Scholar
• Kostine M, Finckh A, Bingham CO 3rd, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2020. DOI:10.1136/annrheumdis-2020-217139.
   PubMed Web of Science ®Google Scholar
• Tahir SA, Gao J, Miura Y, et al., Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci USA. 2019;116(44):22246–22251.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al., Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755.
   PubMed Web of Science ®Google Scholar
• Matas-Garcia A, Milisenda JC, Selva-O’Callaghan A, et al. Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. Autoimmun Rev. 2020;19(2):102455.
   PubMed Web of Science ®Google Scholar
• Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91(10):e985–e994.
   PubMed Web of Science ®Google Scholar
• Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol. 2018;9(9):180.
   PubMed Web of Science ®Google Scholar
• Warner BM, Baer AN, Lipson EJ, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;24(9):1259–1269.
   PubMed Web of Science ®Google Scholar
• Larsabal M, Marti A, Jacquemin C, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863–870.
   PubMed Web of Science ®Google Scholar
• Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67.
   PubMed Web of Science ®Google Scholar
• Ohnuma K, Hatano R, Dang NH, et al. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Mod Rheumatol. 2019;29(5):721–732.
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167.
   PubMed Web of Science ®Google Scholar
• Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152(2):271–281.
   PubMed Web of Science ®Google Scholar
• Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124(2):271–277.
   PubMed Web of Science ®Google Scholar
• Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Dorak MT, Bettinotti MP, et al. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019;58(3):476–480.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–1533.
   PubMed Web of Science ®Google Scholar
• Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–386.
   PubMed Web of Science ®Google Scholar
• Molodtsov A, Turk MJ. Tissue resident CD8 memory T cell responses in cancer and autoimmunity. Front Immunol. 2018;9:2810.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385.
   PubMed Web of Science ®Google Scholar
• Rapisuwon S, Izar B, Batenchuk C, et al. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):61.
   PubMed Web of Science ®Google Scholar
• De Velasco G, Je Y, Bosse D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5(4):312–318.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018;48(3):553–557.
   PubMed Web of Science ®Google Scholar
• Smith MH, Bass AR. Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res (Hoboken). 2019;71(3):362–366.
   PubMed Web of Science ®Google Scholar
• Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186(12):3225–3235.
   PubMed Web of Science ®Google Scholar
• Anderson R, Theron AJ, Rapoport BL. Immunopathogenesis of immune checkpoint inhibitor-related adverse events: roles of the intestinal microbiome and Th17 cells. Front Immunol. 2019;10:2254.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.
   PubMed Web of Science ®Google Scholar
• Almutairi AR, McBride A, Slack M, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol. 2020;10:91.
   PubMed Web of Science ®Google Scholar
• Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44.
   PubMed Web of Science ®Google Scholar
• Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393–398.
   PubMed Web of Science ®Google Scholar
• Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018;17(3):284–289.
   PubMed Web of Science ®Google Scholar
• Buder-Bakhaya K, Benesova K, Schulz C, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018;67(2):175–182.
   PubMed Web of Science ®Google Scholar
• Richter MD, Crowson C, Kottschade LA, et al. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71(3):468–475.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Bingham CO 3rd, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69(11):1751–1763.
   PubMed Web of Science ®Google Scholar
• Pundole X, Abdel-Wahab N, Suarez-Almazor ME. Arthritis risk with immune checkpoint inhibitor therapy for cancer. Curr Opin Rheumatol. 2019;31(3):293–299.
   PubMed Web of Science ®Google Scholar
• Calabrese C, Kirchner E, Kontzias A, et al. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open. 2017;3(1):e000412.
   PubMed Web of Science ®Google Scholar
• Mooradian MJ, Nasrallah M, Gainor JF, et al. Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience. Semin Arthritis Rheum. 2019;48:1127–1132.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76(1):43–50.
   PubMed Web of Science ®Google Scholar
• Braaten TJ, Brahmer JR, Forde PM, et al., Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–338.
   PubMed Web of Science ®Google Scholar
• Michot JM, Fusellier M, Champiat S, et al. Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis. 2019;78(7):e67.
   PubMed Web of Science ®Google Scholar
• Zitouni NB, Arnault JP, Dadban A, et al. Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. Melanoma Res. 2019;29(2):212–215.
   PubMed Web of Science ®Google Scholar
• de Velasco G, Bermas B, Choueiri TK. Autoimmune Arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol. 2016;68(2):556–557.
   PubMed Web of Science ®Google Scholar
• Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211–212.
   PubMed Web of Science ®Google Scholar
• Raschi E, Antonazzo IC, Poluzzi E, et al. Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list? Ann Rheum Dis. 2019. DOI:10.1136/annrheumdis-2019-215819
   PubMed Web of Science ®Google Scholar
• Subedi A, Williams SG, Yao L, et al. Use of magnetic resonance imaging to identify immune checkpoint inhibitor-induced inflammatory arthritis. JAMA Network Open. 2020;3(2):e200032.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Tiongson MD, Stewart C, et al. Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series. J Clin Rheumatol. 2020. DOI:10.1097/RHU.0000000000001370.
   Web of Science ®Google Scholar
• Albayda J, Dein E, Shah A, et al. Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series. ACR Open Rheumatol. 2019;1(5):303–307.
   PubMedGoogle Scholar
• Chan MM, Kefford RF, Carlino M, et al. Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother. 2015;38(1):37–39.
   PubMed Web of Science ®Google Scholar
• Inamo J, Kaneko Y, Takeuchi T. Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment. Clin Rheumatol. 2018;37(4):1107–1110.
   PubMed Web of Science ®Google Scholar
• Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76(10):1747–1750.
   PubMed Web of Science ®Google Scholar
• Leipe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4(2):e000714.
   PubMed Web of Science ®Google Scholar
• Subedi A, Strauss J, Gupta S. Erosive deforming inflammatory arthritis in a patient with cervical adenocarcinoma. JAMA Oncol. 2019;5:1628.
   PubMed Web of Science ®Google Scholar
• Sorensen J, Hetland ML. all departments of rheumatology in D. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74(3):e12.
   PubMed Web of Science ®Google Scholar
• Almoallim H, Janoudi N, Attar SM, et al. Determining early referral criteria for patients with suspected inflammatory arthritis presenting to primary care physicians: a cross-sectional study. Open Access Rheumatol. 2017;9:81–90.
   PubMed Web of Science ®Google Scholar
• Barton JL, Criswell LA, Kaiser R, et al. Systematic review and metaanalysis of patient self-report versus trained assessor joint counts in rheumatoid arthritis. J Rheumatol. 2009;36(12):2635–2641.
   PubMed Web of Science ®Google Scholar
• Chaudhry SR, Thavaneswaran A, Chandran V, et al. Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis. Rheumatology (Oxford). 2013;52(4):705–711.
   PubMed Web of Science ®Google Scholar
• Lo T, Parkinson L, Cunich M, et al. Discordance between self-reported arthritis and musculoskeletal signs and symptoms in older women. BMC Musculoskelet Disord. 2016;17(1):494.
   PubMed Web of Science ®Google Scholar
• Common terminology criteria for adverse events version 5.0. US Department of Health and Human Services. 2017 [cited 2020 May 20]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Woodworth T, Furst DE, Alten R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the rheumatology common toxicity criteria v.2.0. J Rheumatol. 2007;34(6):1401–1414.
   PubMed Web of Science ®Google Scholar
• Stach CM, Sloan VS, Woodworth TG, et al. Rheumatology Common Toxicity Criteria (RCTC): an update reflecting real-world use. Drug Saf. 2019;42(12):1499–1506.
   PubMed Web of Science ®Google Scholar
• Nakamura Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front Med (Lausanne). 2019;6:119.
   PubMed Web of Science ®Google Scholar
• Calabrese C, Cappelli LC, Kostine M, et al. Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open. 2019;5(1):e000906.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013;65(11):2954–2962.
   PubMed Web of Science ®Google Scholar
• Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010;62(9):2787–2795.
   PubMed Web of Science ®Google Scholar
• Chen LF, Mo YQ, Ma JD, et al. Elevated serum IgG4 defines specific clinical phenotype of rheumatoid arthritis. Mediators Inflamm. 2014;2014:635293.
   PubMed Web of Science ®Google Scholar
• Backhaus M, Kamradt T, Sandrock D, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42(6):1232–1245.
   PubMed Web of Science ®Google Scholar
• Klarlund M, Ostergaard M, Jensen KE, et al. Magnetic resonance imaging, radiography, and scintigraphy of the finger joints: one year follow up of patients with early arthritis. The TIRA Group. Ann Rheum Dis. 2000;59(7):521–528.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Carotti M, Ciapetti A, et al. Validity of a computer-assisted manual segmentation software to quantify wrist erosion volume using computed tomography scans in rheumatoid arthritis. BMC Musculoskelet Disord. 2013;14:265.
   PubMed Web of Science ®Google Scholar
• Sudol-Szopinska I, Jans L, Teh J. Rheumatoid arthritis: what do MRI and ultrasound show. J Ultrason. 2017;17(68):5–16.
   PubMed Web of Science ®Google Scholar
• Naredo E, Iagnocco A. One year in review: ultrasound in arthritis. Clin Exp Rheumatol. 2016;34(1):1–10.
   PubMed Web of Science ®Google Scholar
• Duer-Jensen A, Horslev-Petersen K, Hetland ML, et al. Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis Rheum. 2011;63(8):2192–2202.
   PubMed Web of Science ®Google Scholar
• Colebatch AN, Edwards CJ, Ostergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804–814.
   PubMed Web of Science ®Google Scholar
• Dohn UM, Ejbjerg BJ, Court-Payen M, et al. Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther. 2006;8(4):R110.
   PubMed Web of Science ®Google Scholar
• Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med. 2006;31(7):386–390.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen JS. The simplified disease activity index and clinical disease activity index to monitor patients in standard clinical care. Rheum Dis Clin North Am. 2009;35(4):759–772, viii.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5(1):95.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2018;14(4):247–249.
   PubMed Web of Science ®Google Scholar
• Judd J, Zibelman M, Handorf E, et al. Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors. The Oncologist. 2017;22(10):1232–1237.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.
   PubMed Web of Science ®Google Scholar
• Roberts J, Smylie M, Walker J, et al., Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol. 2019;38(5):1513–1519.
   PubMed Web of Science ®Google Scholar
• Calabrese L, Mariette X. Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications. Ann Rheum Dis. 2020;79(3):309–311.
   PubMed Web of Science ®Google Scholar
• Leipe J, Mariette X. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. Rheumatology (Oxford). 2019;58(Suppl 7):vii49–vii58.
   PubMed Web of Science ®Google Scholar
• Libert C, Dejager L. How steroids steer T cells. Cell Rep. 2014;7(4):938–939.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz E, Minute L, Otano I, et al., Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019;569(7756):428–432.
   PubMed Web of Science ®Google Scholar
• Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis. 2017;76(12):2061–2064.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med. 2017;376(20):1989–1991.
   PubMed Web of Science ®Google Scholar
• Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019;93(11):e1093–e1103.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Buhlaiga N, Thebault P, et al. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375–2376.
   PubMed Web of Science ®Google Scholar
• Salem JE, Allenbach Y, Vozy A, et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377–2379.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Calabrese C. The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. Curr Opin Rheumatol. 2020;32(2):175–183.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020 Aug;17(8):504–515.
   Web of Science ®Google Scholar
• Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706–3714.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–2878.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang TO, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to Treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan kettering Cancer Center. J Clin Oncol. 2015;33(28):3193–3198.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. 2018;281(1):57–61.
   PubMed Web of Science ®Google Scholar
• Crossman D, Rothman AMK. Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). J Thorac Dis. 2018;10(Suppl 26):S3084–S3087.
   PubMed Web of Science ®Google Scholar
• Cappelli L, Grieb S, Orbai A et al. “I was prepared for the other side effects; i wasn’t prepared for this one.”: a qualitative study of the patients’ experience of inflammatory arthritis due to immune checkpoint inhibitor therapy for cancer [abstract]. In: 2018 Fig 3AACR/ARHP Annual Meeting. (Ed.^(Eds) (Arthritis & Rheumatology), Chicago, IL, 2018.
   Google Scholar
• Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234–240.
   PubMed Web of Science ®Google Scholar
• Richter MD, Pinkston O, Kottschade LA, et al. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the Mayo Clinic experience. Arthritis Rheumatol. 2018;70(3):356–360.
   PubMed Web of Science ®Google Scholar
• Efuni E, Cytryn S, Boland P, et al. Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. J Clin Rheumatol. 2020. DOI:10.1097/RHU.0000000000001314.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Lopez-Olivo MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med. 2018;169(2):133–134.
   PubMed Web of Science ®Google Scholar
• Dumbrava EE, Suarez-Almazor ME, Painter J, et al. A phase Ib study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO). J clin oncol. 2020;38(15):TPS3158.
   Web of Science ®Google Scholar
• Marshall HT, Djamgoz MBA. Immuno-oncology: emerging targets and combination therapies. Front Oncol. 2018;8:315.
   PubMed Web of Science ®Google Scholar